Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
31 results
D1.125 - Smartphone-Based Asthma Monitoring Using an Audio-Assisted Mouthpiece and STFT-VGG19 Deep Learning Model
D1.132 - Novel CD8+CD122+ Regulatory T Cells Induced by B Cells Suppress T helper 2 Response and Attenuate Eosinophilic Infiltration in Allergic Asthma
D1.123 - Visualization of neutrophil extracellular traps (NETs) and autoantibodies targeting myeloperoxidase (MPO) and neutrophil elastase (NE) in sputum by confocal microscopy
D1.124 - Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study
D1.126 - Therapeutic Splenic Ultrasound Insonation as a Modulator of Pro-atherogenic and Pro-asthmatic Immune Inflammation: A Preclinical Study Design
D1.128 - Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series
D1.130 - Immune markers after one year treatment with benralizumab in severe eosinophilic asthma
D1.131 - Unconventional Group 2 Innate Lymphoid Cells Expressing C-Kit and IL-17A are Increased in Sputum from Severe Asthma with Mixed Granulocytic Airway Inflammation
D1.134 - Type 2 innate lymphoid cells promote development and differentiation of neonatal lung stem/progenitor activity
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort
D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants
D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download